Search

Displaying results 4881 - 4890 of 10000 in total
  1. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. … Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype.

  2. Drug

    Alamifovir

    go.drugbank.com/drugs/DB06368
    Experimental

    Alamifovir is an antiviral agent specific for HBV.

  3. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration. … Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter.

  4. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.

  5. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    ], [vincristine], [prednisone])[L45763] - despite this, as many as 40% of patients will experience relapsed or refractory disease. … In June 2023, the FDA approved the use of glofitamab for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma

  6. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease. … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  7. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. … The vaccine protein is adsorbed to Alhydrogel adjuvant and has been shown to effectively stimulate HTL responses against multiple epitopes in a mouse model.

  8. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  9. Drug

    Atibuclimab

    go.drugbank.com/drugs/DB06546
    Investigational

    Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

    Synonyms: IMMUNOGLOBULIN G4, ANTI-(HUMAN CD14 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL IC14 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL IC14 .KAPPA.-CHAIN, DIMER
  10. Drug

    Aldoxorubicin

    go.drugbank.com/drugs/DB06013
    Investigational

    Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.